Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5174119 | 0.85 | TP53 (0.34) | KMT2ATP53ALOX15MAPK1 | |
| SCHEMBL31098181 | 0.84 | DPP4 (0.44) | DPP4KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL5171835 | 0.82 | DPP4 (0.41) | DPP4KMT2AMEN1ALDH1A1GLA | |
| SCHEMBL14646142 | 0.80 | TAAR1 (0.36) | — | |
| SCHEMBL12913153 | 0.77 | TYR (0.34) | ALDH1A1 | |
| SCHEMBL15972026 | 0.75 | NEK2 (0.34) | DPP4KMT2AALDH1A1TP53ALOX15 | |
| SCHEMBL1408548 | 0.74 | TP53 (0.54) | KMT2AALDH1A1HPGDTP53ALOX15 | |
| SCHEMBL1828118 | 0.74 | LIPG (0.39) | KMT2AMEN1ALDH1A1MAPTTP53 | |
| SCHEMBL8586027 | 0.74 | DPP4 (0.57) | DPP4KMT2AMEN1ALDH1A1GLA | |
| SCHEMBL16697972 | 0.74 | LIPG (0.39) | KMT2AMEN1ALDH1A1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2817304-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BioChromix NewCo AB (SE) | 2014-12-31 | — | — | EP | claimed |
| WO-2013009259-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB (SE) | 2013-01-17 | — | — | WO | claimed |
| US-9359311-B2 | Substituted aromatic oligomers | NEUROSCIOS GMBH (AT) | 2016-06-07 | — | — | US | disclosed |
| US-9359311-B2 | Substituted aromatic oligomers | NEUROSCIOS GMBH (AT) | 2016-06-07 | — | — | US | disclosed |
| US-9359311-B2 | Substituted aromatic oligomers | NEUROSCIOS GMBH (AT) | 2016-06-07 | — | — | US | disclosed |
| US-9012656-B2 | Oligothiophene derivate as molecular probes | CELLUMINOVA AB (SE) | 2015-04-21 | — | — | US | disclosed |
| US-9012656-B2 | Oligothiophene derivate as molecular probes | CELLUMINOVA AB (SE) | 2015-04-21 | — | — | US | disclosed |
| EP-2536712-B1 | OLIGOTHIOPHENE DERIVATE AS MOLECULAR PROBES | CELLUMINOVA AB (SE) | 2015-03-18 | — | — | EP | disclosed |
| EP-2817304-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BioChromix NewCo AB (SE) | 2014-12-31 | — | — | EP | disclosed |
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2014-05-15 | — | — | US | disclosed |
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2014-05-15 | — | — | US | disclosed |
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2014-05-15 | — | — | US | disclosed |
| WO-2013036196-A1 | NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING | BIOCHROMIX AB (SE) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013009259-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB (SE) | 2013-01-17 | — | — | WO | disclosed |
| WO-2013009259-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB (SE) | 2013-01-17 | — | — | WO | disclosed |
| US-20120315646-A1 | OLIGOTHIOPHENE DERIVATE AS MOLECULAR PROBES | CELLUMINOVA AB (SE) | 2012-12-13 | — | — | US | disclosed |
| US-20120315646-A1 | OLIGOTHIOPHENE DERIVATE AS MOLECULAR PROBES | CELLUMINOVA AB (SE) | 2012-12-13 | — | — | US | disclosed |
| WO-2011102789-A1 | OLIGOTHIOPHENE DERIVATE AS MOLECULAR PROBES | OBOE IPR AB (SE) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | PRNP, TBCA, HSPA5 | DPP4 4095/4885KMT2A 4329/4885MEN1 2047/4885 |
| US-20120315646-A1 | OLIGOTHIOPHENE DERIVATE AS MOLECULAR PROBES | NMT1, DNTT, NOTCH4 | DPP4 1879/4885KMT2A 1291/4885MEN1 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.